FDA Approves Ctexli (chenodiol) for Cerebrotendinous Xanthomatosis

Опубликовано: 15 Июль 2026
на канале: Med-Chemist
27
0

FDA Approves Ctexli (chenodiol) for Cerebrotendinous Xanthomatosis


Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced the U.S. Food and Drug Administration (FDA) approval of Ctexli™ (chenodiol) tablets, a bile acid, for the treatment of adults with cerebrotendinous xanthomatosis (CTX). Ctexli is the first and only treatment approved for this rare, progressive and debilitating disease.



https://www.med-chemist.com/2025/11/f...